0.45Open0.45Pre Close0 Volume100 Open Interest12.50Strike Price0.00Turnover117.10%IV12.80%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type0.3536Delta0.1793Gamma25.51Leverage Ratio-0.0458Theta0.0009Rho9.02Eff Leverage0.0066Vega
Indivior Stock Discussion
Groundbreaking Study: New Treatment Option for Pregnant Women Battling Opioid Addiction Shows Promise
Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...
No comment yet